Trending

Sandoz

Fourth Humira biosimilar set for EU approval

Fourth Humira biosimilar set for EU approval

European regulators have backed a new Humira biosimilar for approval, setting up a four-way race for the blockbuster’s

X

Fourth Humira biosimilar set for EU approval

https://pharmaphorum.com/news/humira-biosimilar-eu-sandoz-chmp/

Novartis and Pear to develop substance use digital therapeutics

Novartis and Pear to develop substance use digital therapeutics

Novartis is set to develop and commercialise a range of digital therapeutics for patients with substance and opioid

X

Novartis and Pear to develop substance use digital therapeutics

https://pharmaphorum.com/news/novartis-digital-therapeutics-sandoz-pear/

Biocon and Sandoz strike biosimilars partnership

Biocon and Sandoz strike biosimilars partnership

Companies will develop and market several biosimilars

X

Biocon and Sandoz strike biosimilars partnership

https://pharmaphorum.com/news/biocon-sandoz-strike-biosimilars-partnership/

Novartis files Humira biosimilar in US

Novartis files Humira biosimilar in US

Novartis’ Sandoz division has filed its biosimilar of Humira in the US, aiming to take a share of

X

Novartis files Humira biosimilar in US

https://pharmaphorum.com/news/sandoz-files-humira-biosimilar-us/

Hikma in dispute with FDA over Advair generic

Hikma in dispute with FDA over Advair generic

Hikma to give up date in Q1 next year.

X

Hikma in dispute with FDA over Advair generic

https://pharmaphorum.com/news/hikma-dispute-fda-advair-generic/

Roche under pressure as second rituximab biosimilar filed in US

Roche under pressure as second rituximab biosimilar filed in US

Sandoz is following closely behind rival from Teva and Celltrion.

X

Roche under pressure as second rituximab biosimilar filed in US

https://pharmaphorum.com/news/sandoz-rituximab-biosimilar-us/

Sanofi’s RA drug Kevzara approved in Europe

Sanofi’s RA drug Kevzara approved in Europe

Sanofi’s next-generation rheumatoid arthritis drug Kevzara has been approved in Europe, giving a new option for patients who are

X

Sanofi’s RA drug Kevzara approved in Europe

https://pharmaphorum.com/news/sanofis-kevzara-approved-europe/

Sandoz weighs into European rituximab biosimilar market

Sandoz weighs into European rituximab biosimilar market

Sandoz has gained European approval for its biosimilar version of Roche’s blockbuster MabThera/Rituxan (rituximab) to be called Rixathon. The

X

Sandoz weighs into European rituximab biosimilar market

https://pharmaphorum.com/news/sandoz-weighs-european-rituximab-biosimilar-market/

Sandoz files Humira and Remicade biosimilars in EU

Sandoz files Humira and Remicade biosimilars in EU

European regulators to review Sandoz’s Humira and Remicade biosimilars.

X

Sandoz files Humira and Remicade biosimilars in EU

https://pharmaphorum.com/news/sandoz-biosimilar-humira/

1 2 3

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com